Patients will be served with the announcement of BioNJ Member Amicus Therapeutics’ EU approval for the use of Galafold (Migalastat) in patients with Fabry Disease. Congratulations to John Crowley and BioNJ Board Member Bradley Campbell and the entire
Amicus team. Another grand New Jersey success story!
Meanwhile New Jersey was well represented in San Francisco last week during the world’s largest biotechnology conference, BIO International 2016, with a delegation from New Jersey government, industry, university and trade associations.
New Jersey’s robust life sciences ecosystem was repeatedly and prominently recognized as a leading biotech hotspot throughout the conference. Touted as a national leader, New Jersey was cited as topping the list of states with a high degree of specialization in four of five industry sub-sectors in BIO’s TEConomy report, “The Value of Bioscience Innovation in Growing Jobs and Improving Quality of Life 2016.” Additionally, Scientific American Worldview called New Jersey “America’s Original Biopharmaceutical Heartland,” recognizing the Garden State’s “bumper-to-bumper innovation, first-rate workforce, world class institutions and business friendly resources.”
Congratulations to BioNJ Members Rutgers University and the New Jersey Innovation Institute. They are FINALISTS to apply for a federal grant in which they would establish the Innovative Medicines Manufacturing Institute, the national center for biopharmaceutical manufacturing technology advancement. As the newest member of the National Network for Manufacturing Innovation, it will leverage $70M in federal investment to assist biopharmaceutical companies, regulators and technology suppliers. To learn how your company can benefit from the Institute, contact Mariann Pappagallo at email@example.com.
Earlier this week the “Eds and Meds as an Economic Engine for the City of Camden and the State of New Jersey” was released and features the work being done in South Jersey to develop the life sciences sector in that region. It is impressive what has been achieved there in a short time. Click here to review the report.
Lastly, a big thank you and congratulations to the industry for making all the difference in the lives of Patients and in this case two who are near and dear to my heart. At the 2016 Annual Dinner Meeting in February, I shared that my Mother had just been diagnosed with Stage 4 lung cancer and that former BioNJ Chairman and friend Michael Becker was fighting Stage 4 oropharyngeal cancer. So many of you have checked in to see how they are doing. I am humbled to report that earlier this month we learned that thanks to the steadfast work of this industry, Michael’s PET scan was “perfectly clean” and my Mother’s disease is “25% to 40%” better and she is feeling great. Please click here to read Michael’s inspirational blog. Congratulations and thank you to this awesome industry for making all the difference.
I hope to see you all at BioNJ’s Third Annual Diagnostics & Precision Medicine Summit taking place next Tuesday, June 21, and our Inspiring Women in STEM Symposium on Tuesday, June 28. Visit www.BioNJ.org to learn about these and other upcoming BioNJ events.
Click here to read this week’s Weekender.